RxDoctor Payments Data

Thomas Golubski, MD

Nephrology · Merrillville, INNPI 1639176118

Payments from drug & device makers

$1,454in general payments, 2019–2025

Across 49 payments — averaging $29.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nxstage Medical, Inc.$506
  • AstraZeneca$218
  • Fresenius USA Marketing, Inc.$165
  • Amgen$107
  • Outset Medical Inc$101
  • Vifor Pharma, Inc.$46
  • plus $311 from 14 others

What the payments were for

  • Food & beverage$1,43499%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,454 in reported general payments places this provider in the 55th percentile of 238 nephrology providers in Indiana.

See all nephrology providers in Indiana

Medicare billing

Part B allowed, 2024
$208,505
Medicare patients
219
Services billed
1,804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide55$162,445
AuryxiaFerric Citrate40$86,263
Sevelamer Carbonate113$22,302
FarxigaDapagliflozin Propanediol19$18,849
EntrestoSacubitril/Valsartan12$10,633
LokelmaSodium Zirconium Cyclosilicate18$9,886
Calcitriol39$640
Hydralazine Hcl26$483
Allopurinol61$474
Potassium Chloride25$404
Furosemide69$353
Tamsulosin Hcl18$321
Amlodipine Besylate60$290
Enalapril Maleate15$253
Gabapentin13$218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$165$162,44555 claims
Akebia Therapeutics IncAuryxia$21$86,26340 claims
AstraZenecaFarxiga, Lokelma$218$28,73537 claims
NovartisEntresto$29$10,63312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 238 nephrology providers in Indiana.

Other nephrology in Merrillville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →